ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 1 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $552,289 | +48.2% | 5,898 | +41.3% | 0.26% | +50.6% |
Q2 2023 | $372,619 | -52.6% | 4,175 | -43.1% | 0.17% | -73.5% |
Q1 2023 | $786,780 | -12.2% | 7,338 | 0.0% | 0.64% | +20.5% |
Q4 2022 | $896,190 | -11.3% | 7,338 | -25.0% | 0.53% | -7.8% |
Q3 2022 | $1,010,000 | +46.0% | 9,780 | +31.4% | 0.58% | +38.0% |
Q2 2022 | $692,000 | -24.6% | 7,442 | -4.8% | 0.42% | -28.4% |
Q1 2022 | $918,000 | -20.1% | 7,821 | -8.4% | 0.58% | -36.2% |
Q4 2021 | $1,149,000 | -26.2% | 8,541 | -12.6% | 0.92% | -11.2% |
Q3 2021 | $1,557,000 | +95.4% | 9,769 | +61.2% | 1.03% | +82.3% |
Q2 2021 | $797,000 | +12.4% | 6,060 | +10.1% | 0.56% | +7.2% |
Q1 2021 | $709,000 | -10.1% | 5,505 | +16.4% | 0.53% | +4.6% |
Q4 2020 | $789,000 | +54.7% | 4,731 | +43.1% | 0.50% | +35.5% |
Q3 2020 | $510,000 | +19.2% | 3,307 | +14.3% | 0.37% | +5.1% |
Q2 2020 | $428,000 | – | 2,893 | – | 0.35% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 10,719,555 | $1,003,779,130 | 19.76% |
Q Global Advisors, LLC | 285,000 | $26,687 | 17.16% |
Finepoint Capital LP | 163,772 | $15,335,610 | 7.64% |
Avoro Capital Advisors LLC | 3,670,000 | $343,658,800 | 5.36% |
Spyglass Capital Management LLC | 614,618 | $57,552,830 | 4.51% |
Sofinnova Investments, Inc. | 754,032 | $70,607,556 | 4.45% |
Saturn V Capital Management LP | 112,473 | $10,531,972 | 4.41% |
DAFNA Capital Management LLC | 136,212 | $12,754,892 | 3.97% |
ARS Investment Partners, LLC | 285,918 | $26,773,362 | 3.32% |
Ghost Tree Capital, LLC | 85,000 | $7,959,400 | 2.62% |